Cerity Partners LLC Increases Stock Position in Illumina, Inc. $ILMN

Cerity Partners LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 23.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 125,387 shares of the life sciences company’s stock after acquiring an additional 23,417 shares during the quarter. Cerity Partners LLC owned 0.08% of Illumina worth $11,908,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of ILMN. Parkside Financial Bank & Trust boosted its holdings in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares during the period. Cullen Frost Bankers Inc. bought a new position in Illumina during the 2nd quarter valued at about $41,000. NewSquare Capital LLC raised its stake in Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after buying an additional 369 shares during the last quarter. Mather Group LLC. purchased a new position in Illumina in the third quarter worth about $46,000. Finally, SJS Investment Consulting Inc. increased its holdings in Illumina by 13,225.0% during the third quarter. SJS Investment Consulting Inc. now owns 533 shares of the life sciences company’s stock valued at $51,000 after buying an additional 529 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 3.3%

Illumina stock opened at $141.07 on Friday. The firm has a market cap of $21.56 billion, a PE ratio of 31.63, a P/E/G ratio of 2.35 and a beta of 1.41. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The stock’s 50 day simple moving average is $130.01 and its two-hundred day simple moving average is $109.77. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $153.06.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The company’s revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Buying and Selling at Illumina

In related news, Director Scott Gottlieb purchased 500 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was bought at an average price of $122.13 per share, with a total value of $61,065.00. Following the acquisition, the director owned 12,523 shares in the company, valued at $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott M. Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ILMN shares. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. JPMorgan Chase & Co. raised their target price on shares of Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Canaccord Genuity Group increased their target price on shares of Illumina from $112.00 to $130.00 and gave the stock a “hold” rating in a report on Monday, December 22nd. Barclays boosted their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $122.56.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.